MEP41008A - Use of bradykinin-b2 receptor antagonists for treating osteoarthrosis - Google Patents

Use of bradykinin-b2 receptor antagonists for treating osteoarthrosis

Info

Publication number
MEP41008A
MEP41008A MEP-410/08A MEP41008A MEP41008A ME P41008 A MEP41008 A ME P41008A ME P41008 A MEP41008 A ME P41008A ME P41008 A MEP41008 A ME P41008A
Authority
ME
Montenegro
Prior art keywords
bradykinin
receptor antagonists
diseases
treating osteoarthrosis
osteoarthrosis
Prior art date
Application number
MEP-410/08A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
Martin Michaelis
Karl Rudolphi
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MEP41008A publication Critical patent/MEP41008A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/043Kallidins; Bradykinins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MEP-410/08A 2003-02-07 2004-01-23 Use of bradykinin-b2 receptor antagonists for treating osteoarthrosis MEP41008A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10304994A DE10304994A1 (de) 2003-02-07 2003-02-07 Die Verwendung von Antagonisten des Bradykinin-B2 Rezeptors zur Behandlung von Osteoarthrose
YUP-2005/0565A RS51029B (sr) 2003-02-07 2004-01-23 Upotreba antagonista bradikinin-b2 receptora za lečenje osteoartroze
PCT/EP2004/000550 WO2004069266A2 (de) 2003-02-07 2004-01-23 Die verwendung von antagonisten des bradykinin-b2 rezeptors zur behandlung von osteoarthrose

Publications (1)

Publication Number Publication Date
MEP41008A true MEP41008A (en) 2011-02-10

Family

ID=32797325

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-410/08A MEP41008A (en) 2003-02-07 2004-01-23 Use of bradykinin-b2 receptor antagonists for treating osteoarthrosis

Country Status (31)

Country Link
EP (1) EP1594520B1 (es)
JP (1) JP2006516980A (es)
KR (1) KR20050105447A (es)
CN (1) CN1317029C (es)
AR (1) AR043036A1 (es)
AT (1) ATE335500T1 (es)
AU (1) AU2004210396A1 (es)
BR (1) BRPI0407333A (es)
CA (1) CA2514152C (es)
CO (1) CO5690613A2 (es)
CY (1) CY1105708T1 (es)
DE (2) DE10304994A1 (es)
DK (1) DK1594520T3 (es)
ES (1) ES2268622T3 (es)
HK (1) HK1085926A1 (es)
HR (1) HRP20050701B1 (es)
IL (1) IL169899A0 (es)
MA (1) MA27618A1 (es)
ME (1) MEP41008A (es)
MX (1) MXPA05007310A (es)
MY (1) MY135827A (es)
NO (1) NO333903B1 (es)
NZ (1) NZ541680A (es)
PE (1) PE20040939A1 (es)
PL (1) PL206412B1 (es)
PT (1) PT1594520E (es)
RS (1) RS51029B (es)
RU (1) RU2329057C2 (es)
TW (1) TW200505472A (es)
WO (1) WO2004069266A2 (es)
ZA (1) ZA200505177B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0710522D0 (en) * 2007-06-01 2007-07-11 Royal Veterinary College The Drug delivery system comprising matrix metalloproteinase inhibitors
IT1391236B1 (it) 2008-07-11 2011-12-01 St Luso Farm D'italia Spa Composizioni farmaceutiche a base di antagonisti del recettore b2 delle chinine e corticosteroidi e loro uso

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE63490B1 (en) * 1988-11-24 1995-05-03 Hoechst Ag Peptides having bradykinin antagonist action
MX9100717A (es) * 1990-08-24 1992-04-01 Syntex Inc Antagonistas de la bradiquinina
FR2751650B1 (fr) * 1996-07-24 1998-10-09 Fournier Ind & Sante Nouveaux composes de n-benzenesulfonyl-l-proline, procede de preparation et utilisation en therapeutique
CA2364178C (en) * 2000-12-05 2006-01-10 Yasuhiro Katsu N-benzenesulfonyl l-proline compounds as bradykinin antagonists
AU2003212898B2 (en) * 2002-02-01 2008-10-02 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation

Also Published As

Publication number Publication date
IL169899A0 (en) 2011-08-01
DE502004001159D1 (de) 2006-09-21
NO333903B1 (no) 2013-10-14
CA2514152A1 (en) 2004-08-19
ES2268622T3 (es) 2007-03-16
TW200505472A (en) 2005-02-16
DE10304994A1 (de) 2004-09-02
NZ541680A (en) 2009-07-31
KR20050105447A (ko) 2005-11-04
BRPI0407333A (pt) 2006-01-10
EP1594520A2 (de) 2005-11-16
HRP20050701A2 (en) 2006-09-30
PL206412B1 (pl) 2010-08-31
WO2004069266A3 (de) 2004-09-30
ATE335500T1 (de) 2006-09-15
PT1594520E (pt) 2006-11-30
CN1317029C (zh) 2007-05-23
CA2514152C (en) 2012-01-17
WO2004069266A2 (de) 2004-08-19
DK1594520T3 (da) 2006-12-11
CN1747742A (zh) 2006-03-15
NO20054144L (no) 2005-09-06
RS51029B (sr) 2010-10-31
HRP20050701B1 (hr) 2014-01-03
RU2329057C2 (ru) 2008-07-20
ZA200505177B (en) 2006-11-29
EP1594520B1 (de) 2006-08-09
PL376605A1 (pl) 2006-01-09
AU2004210396A1 (en) 2004-08-19
PE20040939A1 (es) 2005-01-17
RU2005127862A (ru) 2006-01-27
MXPA05007310A (es) 2005-09-30
CO5690613A2 (es) 2006-10-31
HK1085926A1 (en) 2006-09-08
RS20050565A (en) 2007-09-21
JP2006516980A (ja) 2006-07-13
MY135827A (en) 2008-07-31
MA27618A1 (fr) 2005-11-01
AR043036A1 (es) 2005-07-13
CY1105708T1 (el) 2010-12-22

Similar Documents

Publication Publication Date Title
EA200900211A1 (ru) Замещенные производные имидазолона, их получение и применение
EA200800555A1 (ru) Производные ксантина в качестве селективных агонистов hm74a
EA200800157A1 (ru) Антагонисты npy, способ их получения и применение
CY1116800T1 (el) Συνθεσεις και μεθοδοι χρησης για θεραπευτικα αντισωματα
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
ATE477252T1 (de) Substituierte diazepane als antagonisten an orexinrezeptoren
UA111579C2 (uk) ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ
PA8493701A1 (es) Compuestos para tratar la obesidad
BRPI0512274A (pt) derivados de piperazina aril-substituìdos
CY1109624T1 (el) Υποκατεστημενα παραγωγα θειοφαινιου ως ανταγωνιστες υποδοχεα γλυκογονου, παρασκευη και θεραπευτικες χρησεις
MA29088B1 (fr) Composes d'indazole-carboxamide.
BRPI0613859A8 (pt) compostos derivados de nitrocatecol, seu uso e seu processo de preparação, bem como composição farmacêutica
NO20092470L (no) Substituerte diazepanforbindelser som orexinreseptorantagonister
BR112012013431A2 (pt) composto, composição farmacêutica e seu uso
BRPI0411840A2 (pt) Método e aparelho para tratar osteoartrite, doença da cartilagem, defeitos e ferimentos no joelho humano.
DE602004012858D1 (de) 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
BRPI0417376A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
BRPI0713443A2 (pt) Derivados de piperazinila úteis no tratamento de doenças medianas por receptor gpr38, uso e composição farmacêutica contendo tais compostos e processos para preparação dos mesmos
BRPI0507120A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
EA200501595A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
EA200600071A1 (ru) Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
ATE495164T1 (de) Thiadiazolderivate zur behandlung neurodegenerativer krankheiten
DE69922528D1 (de) N-imidazolyl-alkyl substituierte cyklische amine als histamin-h3 agonisten oder antagonisten
MA32224B1 (fr) Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales
DE60108094D1 (de) Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologien